Cargando…
JAK inhibition for treatment of psoriatic arthritis in Down syndrome
Autores principales: | Pham, Andrew T., Rachubinski, Angela L., Enriquez-Estrada, Belinda, Worek, Kayleigh, Griffith, Melissa, Espinosa, Joaquin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410001/ https://www.ncbi.nlm.nih.gov/pubmed/33630031 http://dx.doi.org/10.1093/rheumatology/keab203 |
Ejemplares similares
-
Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition
por: Galbraith, Matthew D., et al.
Publicado: (2023) -
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
por: Suruki, Robert Y, et al.
Publicado: (2022) -
Vitamin D-resistant osteomalacia after 10 years of haemodialysis in a patient with rheumatoid arthritis
por: Hatano, Masaki, et al.
Publicado: (2021) -
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
por: Rachubinski, Angela L., et al.
Publicado: (2019) -
Comment on: The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use. Reply
por: Smeele, Hieronymus T W, et al.
Publicado: (2021)